Circulating alpha-fetoprotein-specific T-cell responses are associated with clinical outcomes after radiofrequency ablation or immunotherapy in hepatocellular carcinoma
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Circulating tumor antigen-specific T-cell responses are promising peripheral immune biomarkers associated with treatment efficacy, yet clinical translation is hampered by incomplete epitope maps and non-standardized assays. This study aimed to map the T-cell epitope repertoire of AFP and develop a PBMC-based assay to quantify circulating AFP-specific T-cell responses in HCC. METHODS: CD8+ T-cell epitopes in AFP were screened using in silico prediction, peptide-PBMC coculture, peptide competitive binding assays, and immunization in HLA-transgenic mice, and then applied in clinical cohorts. RESULTS: Totally, 48 CD8+ T-cell epitopes identified here and 20 from our previous study were confirmed immunogenic. These peptides were used to establish an IFN-γ ELISpot assay for quantifying circulating AFP-specific T-cell responses in PBMCs. A total of 170 HCC patients with elevated serum AFP were included in two derivation cohorts: 80 patients treated with RFA and 90 receiving anti-PD-1 plus anti-VEGF therapy. In the RFA derivation cohort, the post-treatment/pre-treatment fold of AFP-specific T-cell responses was independently associated with DFS (AUC, 0.838; cutoff, 1.95-fold for DFS >12 vs. ≤12 mo). In the anti-PD-1 plus anti-VEGF derivation cohort, the post-treatment/pre-treatment fold of AFP-specific T-cell responses was independently associated with objective response and 6-month PFS (AUC, 0.850 and 0.863, respectively), with a unified 2.5-fold cutoff for outcome stratification. These findings in the immunotherapy setting were further validated in an independent external cohort of 50 HCC patients with elevated serum AFP receiving combined anti-PD-1 and anti-VEGF therapy. CONCLUSIONS: This study establishes an IFN-γ ELISpot assay for quantifying circulating AFP-specific T-cell responses in PBMCs and supports their potential translational utility as a novel peripheral immune-monitoring biomarker associated with clinical outcomes in AFP-positive HCC patients.
Source: Hepatology Communications
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,700
OpenAlex ID: W7236575584
